Nuvectis Pharma, Inc. (NVCT)
NASDAQ: NVCT · Real-Time Price · USD
6.44
+0.34 (5.57%)
Jan 23, 2025, 12:22 PM EST - Market open
Nuvectis Pharma Employees
Nuvectis Pharma had 13 employees as of December 31, 2023. The number of employees increased by 2 or 18.18% compared to the previous year.
Employees
13
Change (1Y)
2
Growth (1Y)
18.18%
Revenue / Employee
n/a
Profits / Employee
-$1,490,308
Market Cap
124.43M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 13 | 2 | 18.18% |
Dec 31, 2022 | 11 | 3 | 37.50% |
Dec 31, 2021 | 8 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
NVCT News
- 2 months ago - Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug - Benzinga
- 2 months ago - Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire
- 3 months ago - PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update - Business Wire
- 5 months ago - Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers - GlobeNewsWire
- 6 months ago - Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire
- 9 months ago - Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference - GlobeNewsWire
- 9 months ago - Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire
- 10 months ago - Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines - GlobeNewsWire